Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizotinib in Tumors With MET Exon 14 Deletion (MATCH Subprotocol C2)
NCT06360575Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2016
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of crizotinib in malignant solid neoplasm, lymphoma, multiple myeloma (MM), sponsored by National Cancer Institute. Started Jul 2016; status: active, not recruiting.
02
Drugs
crizotinib
03
Conditions
malignant solid neoplasmlymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT06360575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06360575.